Blair William & Co. IL lowered its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 7.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,270,019 shares of the biopharmaceutical company's stock after selling 192,304 shares during the period. Blair William & Co. IL's holdings in Pfizer were worth $60,224,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer during the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $32,000. Institutional investors own 68.36% of the company's stock.
Wall Street Analysts Forecast Growth
PFE has been the subject of a number of research analyst reports. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Bank of America reaffirmed a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.
View Our Latest Report on Pfizer
Pfizer Stock Performance
PFE stock traded up $0.19 on Friday, hitting $25.20. The company had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The stock's 50-day simple moving average is $26.06 and its 200 day simple moving average is $26.92.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 EPS. The business's quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Insider Transactions at Pfizer
In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
